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Adenoviral vectors have been exploited for a wide range of gene therapy applications. Direct genetic modification of the adenovirus
capsid proteins has been employed to achieve alteration of vector tropism. We have defined the carboxy-terminus of the minor capsid protein
pIX as a locus capable of presenting incorporated ligands on the virus capsid surface. Thus, we sought to exploit the possibility of
incorporating functional proteins at pIX. In our current study, we incorporated the herpes simplex virus type 1 (HSV-1) thymidine kinase
(TK) within pIX to determine if a larger protein of this type could retain functionality in this context. Our study herein clearly demonstrates
our ability to rescue viable adenoviral particles that display functional HSV-1 TK as a component of their capsid surface. DNA packaging and
cytopathic effect were not affected by this genetic modification to the virus, while CAR-dependent binding was only marginally affected.
Using an in vitro [3H]-thymidine phosphorylation assay, we demonstrated that the kinase activity of the protein IX-TK fusion protein
incorporated into adenoviral virions is functional. Analysis of cell killing after adenovirus infection showed that the protein IX-TK fusion
protein could also serve as a therapeutic gene by rendering transduced cells sensitive to gancyclovir. Using 9-[4-[18F]-fluoro-3-
(hydroxymethyl)butyl]guanine ([18F]-FHBG; a positron-emitting TK substrate), we demonstrated that we could detect specific cell binding
and uptake of adenoviral virions containing the protein IX-TK fusion protein at 1 h post-infection. Our study herein clearly demonstrates our
ability to rescue viable adenoviral particles that display functional HSV-1 TK as a component of their capsid surface. The alternative display
of HSV-1 TK on the capsid may offer advantages with respect to direct functional applications of this gene product. In addition, the
determination of an expanded upper limit of incorporable proteins on pIX highlights its unique utility as a locus for placement of functional
vector constructs.
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Adenoviral vectors have been exploited for a wide range
of gene therapy applications (Glasgow et al., 2004). This
utility derives from the unparalleled efficiency of gene
transfer for both in vitro and in vivo delivery contexts
(Mizuguchi and Hayakawa, 2004). Additional advantages
derive from the plasticity of the adenoviral system, which
permits directed vector modification for the achievement of
selected functional gains (Rots et al., 2003). In this regard,
genetic modification of the capsid proteins has been
employed to achieve alteration of vector tropism for05) 247 – 258
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selected capsid engineering steps have proved a useful
means to circumvent the host anti-vector immune response
directed against antigenic epitopes (Wu et al., 2002). More
recently, the incorporation of the imaging motif enhanced
green fluorescent protein (EGFP) (Le et al., 2004; Meulen-
broek et al., 2004) has introduced the concept that functional
motifs can be incorporated within the adenoviral capsid,
thereby expanding the repertoire of utilities potentially
combined within a single vector particle.
The basis of this evolving paradigm stems from the
recent identification of capsid locales permissive of incor-
porating larger and/or more complex protein moieties
(Volpers and Kochanek, 2004). In this regard, previous
reports have defined clear size limits with respect to
heterologous proteins incorporable at the major capsid
proteins (Belousova et al., 2002; Pereboeva et al., 2004),
which effectively limited the repertoire of capsid-incorpo-
rated motifs to small linear peptides. Our more recent work
has defined the carboxy-terminus of the minor capsid
protein pIX as a locus capable of presenting incorporated
ligands on the virus capsid surface (Dmitriev et al., 2002).
Of note, we have shown the pIX-incorporated EGFP is fully
functional, allowing visualization of labeled viral particles
for analytical purposes (Le et al., 2004).
Based on these established feasibilities, we sought to
exploit the possibility of incorporating additional functional
proteins at the capsid protein pIX. In this context, herpes
simplex virus type 1 (HSV-1) thymidine kinase (TK) has
been utilized both for molecular chemotherapy cancer gene
therapy applications and as an agent in PET-based imaging
schemas (Herschman, 2002). In our current study, we
sought to incorporate HSV-1 TK within pIX to determineFig. 1. Recombinant adenovirus constructs. (A) Ad-wt-pIX-TK, an Ad5 construct c
construct containing HSV-1 TK in place of the Ad E3 gene, (C) control virus Ad-w
virus Ad-wt-E3-CD, an Ad5 construct containing cytosine deaminase in place ofif a larger protein of this type could retain functionality in
this context. Our study herein clearly demonstrates our
ability to rescue viable adenoviral particles that display
functional HSV-1 TK as a component of their capsid
surface. The alternative display of HSV-1 TK on the capsid
may offer advantages with respect to direct functional
applications of this gene product. In addition, the determi-
nation of an expanded upper limit of incorporable proteins
on pIX highlights its unique utility as a locus for placement
of functional vector components.Results
Construction of Ad-wt-pIX-TK
An E3-deleted adenovirus shuttle plasmid was con-
structed containing a pIX-TK carboxy-terminal fusion gene
in place of wild-type pIX. Between the pIX and TK coding
regions, we incorporated an 18 amino acid linker, SAD-
DYKDDDDKLAGSGSG, containing the octapeptide
DYKDDDDK FLAG-tag sequence. This shuttle plasmid
was used to construct an E3-deleted adenovirus (Ad-wt-
pIX-TK; Fig. 1A), which was successfully rescued. As a
control, an E3-deleted adenovirus vector was constructed,
which contained the TK gene replacing the E3 region, under
regulation by the adenovirus early gene promoter (Ad-wt-
E3-TK; Fig. 1B). As additional controls, an E3-deleted
adenovirus vector, which lacked any TK gene, was
constructed (Ad-wt-dE3; Fig. 1C), as was an E3-deleted
adenovirus vector, which contained the CD gene replacing
the E3 region, under regulation by the adenovirus early gene
promoter (Ad-wt-E3-CD; Fig. 1D).ontaining a pIX-TK fusion protein, (B) control virus Ad-wt-E3-TK, an Ad5
t-dE3, a wild-type Ad5 in which the E3 gene has been deleted, (D) control
the Ad E3 gene.
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Propagated Ad-wt-pIX-TK was purified by double CsCl
ultracentrifugation where the top and bottom bands were
preserved. The resulting gradient of virus was fractionated
and analyzed for DNA content by absorbance at 260 nm. A
major DNA content peak was present in the bottom band
where mature, infectious virions normally migrate, as well
as a minor peak where immature, empty virions normally
migrate (Fig. 2A). Infectious, mature Ad-wt-pIX-TK
particles were present in the bottom band as indicated by
an infectivity peak in a c.p.e. assay (data not shown). The
same gradient fractions of Ad-wt-pIX-TK were also
analyzed with Western blots using a FLAG-tag antibody.
As shown in Fig. 2B, accumulations of pIX-TK were
detected in both the top and bottom band regions for Ad-
wt-pIX-TK, confirming the co-localization of pIX-TK with
the virions.
Cytopathic effect of Ad-wt-pIX-TK
To quantitatively evaluate viral cytotoxicity, survival of
911 cells after infection with Ad-wt-pIX-TK, and control
Ad-wt-E3-TK and Ad-wt-dE3 viruses (at 0.01, 0.1, and 1.0
infectious units (i.f.u.)/cell), were monitored over 10 days
(Fig. 3). On days 0, 2, 4, 6, 8, and 10, the cytopathic effect
of the virus was quantitated using a non-radioactive cell
proliferation MTS assay. In all concentrations of virus used,
Ad-wt-pIX-TK cytopathic effect on 911 cells was the same
as that of both Ad-wt-E3-TK and Ad-wt-dE3. TheseFig. 2. CsCl gradient fraction DNA content and Western blot followed double ultra
TK was determined by measuring absorbance at 260 nm. (B) Individual fractio
following SDS–PAGE and transfer to PVDF membranes.findings indicate that pIX-TK incorporation did not affect
the cytopathic capacity and lateralization of the virus.
CAR-dependent binding of Ad-wt-pIX-TK
The coxsackie adenovirus receptor binding ability of Ad-
wt-pIX-TK was determined by allowing the virus to bind to
cells and quantitating the bound virus with TaqMan
quantitative real-time PCR (Fig. 4). Ad-wt-pIX-TK binding
to CAR (+) A549 cells was much higher than that of CAR
() CHO cells. In addition, recombinant fiber-knob block
mitigated the CAR-dependent binding of Ad-wt-pIX-TK to
A549 cells. Blocking had no effect on the binding of Ad-wt-
pIX-TK to CHO cells. Overall, Ad-wt-pIX-TK appeared to
show similar binding compared to Ad-wt-E3-TK; in
addition, the CAR-dependent binding trend was very similar
between Ad-wt-pIX-TK and Ad-wt-E3-TK. These results
indicate that the capsid fusion protein label did not interfere
with the ability of Ad-wt-pIX-TK to recognize its primary
receptor CAR.
Thermostability of Ad-wt-pIX-TK
Modification of pIX may destabilize the capsid structure;
comparing the thermostability of Ad-wt-pIX-TK to that of
control Ad-wt-E3-TK assessed this possibility. Virus sam-
ples were incubated at 45 -C for various time periods and
then quantitated in terms of infectious titer (Fig. 5). Up to 5
min of incubation, the infectious titer of Ad-wt-pIX-TK
remained the same as that of control. After 5 min ofcentrifugation. (A) DNA content of individual fractions (?) of Ad-wt-pIX-
ns were analyzed for pIX-TK fusion protein using an anti-Flag antibody
Fig. 3. Cytopathic effect. The cytopathic effect of Ad-wt-dE3 (?), Ad-wt-E3-TK ( ), and Ad-wt-pIX-TK ( ) in 911 cells was determined at three different
multiplicities of infection: (A) 0.01 i.f.u., (B) 0.1 i.f.u., and (C) 1.0 i.f.u. Cytotoxicity measured by non-radioactive MTS proliferation assay and expressed as
percent of survival cells (mean T standard deviation of three replicates).
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wt-E3-TK was about 60% and 80% of initial titers. Viral
titers continued to decrease between 10 and 20 min of
incubation, and the titers of Ad-wt-pIX-TK and Ad-wt-E3-
TK were not significantly different from each other. These
results indicate that the TK addition to pIX did not affect the
thermostability of Ad-wt-pIX-TK following exposure of the
virus to high temperature compared to a virus containing
wild-type pIX.Fig. 4. Car-dependent binding of Ad-wt-pIX-TK compared to Ad-wt-E3-
TK. After binding and infection of 2  105 CHO (CAR-negative) or 2 
105 A549 (CAR-positive) cells with 1  109 i.f.u. virus, Ad-wt-E3-TK (h)
and Ad-wt-pIX-TK ( ) viral replications were quantitated by real-time
PCR of E4 transcripts as described in Materials and methods (values are
expressed as mean T standard deviation of three replicates). Duplicate
groups were initially blocked with recombinant fiber knob prior to binding
and infection with Ad-wt-E3-TK (g) or Ad-wt-pIX-TK ( ).GCV cytotoxicity assays
In order to determine the growth characteristics of cells
treated with a pharmacologic concentration of GCV, 911 cells
were initially infected with increasing doses of Ad-wt-pIX-
TK ranging from 10 to 1000 v.p./cell. As controls, 911 cells
were incubated with increasing doses of either Ad-wt-E3-TK
or Ad-wt-E3-CD. At 12 h post-infection, the cells were
incubated in the absence or presence of 1.0 mM GCV for 4
days, and cell viability was determined using an MTS assay.
As anticipated (Fig. 6), incubation of the cells with increasing
doses of any of the adenoviruses resulted in a cytopathicFig. 5. Thermostability of Ad-wt-pIX-TK compared to Ad-wt-E3-TK. The
thermostability of both of Ad-wt-pIX-TK ( ) and Ad-wt-E3-TK (h) was
determined. Both viruses were incubated at high temperature for various
time periods and quantitated by infecting in terms of infectious titer as
described in Materials and methods (values are expressed as mean T
standard deviation of three replicates).
Fig. 6. Cell killing with increasing doses of virus in the absence or presence of GCV. A cell-killing assay was used to determine cell survival after infection with
Ad-wt-E3-CD (at 10, 100, and 1000 v.p./cell), Ad-wt-E3-TK (at 10, 100, and 1000 v.p./cell), or Ad-wt-pIX-TK (at 10, 100, and 1000 v.p./cell). At 12 h post-
infection, the cells were incubated in the absence or presence of 1.0 mM GCV for 4 days, and cell viability was determined using an MTS assay. The values are
expressed as mean T standard deviation of three replicates. Titers for the viruses were: Ad-wt-E3-TK, 58.0 v.p./i.f.u.; Ad-wt-pIX-TK, 86.0 v.p./i.f.u.; and Ad-
wt-E3-CD, 274 v.p./i.f.u.
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GCV caused an increased cytopathic effect in cells infected
with either Ad-wt-pIX-TK or with Ad-wt-E3-TK. In cells
infected with Ad-wt-E3-CD, however, no additional cyto-
pathic effect was observed by the addition of GCV.
Cells infected with Ad-wt-E3-TK appeared to be more
sensitive to the effect of GCV than cells infected with Ad-
wt-pIX-TK; doses at 10 v.p./cell and at 100 v.p./cell, a
greater cytopathic effect was detected in GCV-treated cells
previously infected with Ad-wt-E3-TK than with Ad-wt-
pIX-TK. This observation could be due to a difference in
TK gene expression in cells infected with Ad-wt-E3-TK
compared to cells infected with Ad-wt-pIX-TK. Alterna-Fig. 7. Cell killing with virus and increasing doses of GCV. A cell-killing assay was
and 1.0 i.f.u./cell), Ad-wt-E3-TK (at 0.01, 0.1, and 1.0 i.f.u./cell), or Ad-wt-pIX-
incubated in the presence of GCVat 0 (h), 0.125 (h), 0.250 ( ), 0.500 ( ), 0.750
MTS assay. The values are expressed as mean T standard deviation of three replic
TK, 86.0 v.p./i.f.u.; and Ad-wt-dE3, 521 v.p./i.f.u.tively, this observation could be due to differences in
enzymatic activity between the wild-type TK and the pIX-
TK fusion protein. To differentiate between these two
possibilities, real-time RT-PCR was used to assess TK
RNA levels in total RNA isolated from 911 cells infected
with equivalent infectious amounts of either Ad-wt-E3-TK
(0.1 i.f.u./cell) or Ad-wt-pIX-TK (0.1 i.f.u./cell). The results
of this assay detected an 18-fold relative increase in TK
expression in cells infected for 2 days with Ad-wt-E3-TK
compared to cells infected with Ad-wt-pIX-TK (data not
shown).
In the experiment shown in Fig. 7, the cells were initially
infected as before for 12 h with Ad-wt-pIX-TK rangingused to determine cell survival after infection with Ad-wt-dE3 (at 0.01, 0.1,
TK (at 0.01, 0.1, and 1.0 i.f.u./cell). At 12 h post-infection, the cells were
( ), and 1.00 mM ( ) for 4 days, and cell viability was determined using an
ates. Titers for the viruses were: Ad-wt-E3-TK, 58.0 v.p./i.f.u.; Ad-wt-pIX-
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incubated with increasing doses of either Ad-wt-E3-TK or
Ad-wt-dE3. The cells were then incubated with a variety of
concentrations of GCV (ranging from 0.125 to 1.0 mM) for
4 days, and cell viability was determined by MTS assay. The
viability of cells infected with either Ad-wt-pIX-TK or with
Ad-wt-E3-TK was inhibited at similar concentrations (ED50
at approximately 0.5 mM). By contrast, the viability of cells
infected with Ad-wt-dE3 showed no growth inhibition from
any concentration of GCV. These results demonstrate that
the wild-type TK and the pIX-TK fusion proteins had
similar activities on growth inhibition in the presence of
GCV.
HSV-1 TK enzymatic activity
HSV-1 TK enzymatic activity associated with the
purified Ad-wt-pIX-TK virions was determined by monitor-
ing the incorporation and conversion of [3H]-thymidine
substrate into the phosphorylated product (Fig. 8). In these
experiments, enzymatic activity of the pIX-TK protein
incorporated into virions was determined directly in vitro.
As shown in Fig. 8A, incubation of [3H]-thymidine with
increasing amounts of purified Ad-wt-pIX-TK virus in vitro
for 35 min resulted in conversion of up to 40.7% [3H]-
thymidine into the phosphorylated form. Importantly, Ad-
wt-E3-TK showed minimal conversion of [3H]-thymidine
(0.23%) at the highest amount of purified virus used. To
confirm these results, at time course analysis was performed
from 5 to 40 min with various amounts of purified Ad-wt-
pIX-TK virus. As shown in Fig. 8B, a time-dependent
increase in substrate conversion was observed with hyper-Fig. 8. Characterization of in vitro TK activity in Ad-wt-pIX-TK virions. Using
phosphorylation of 3H-thymidine after 35-min incubation. (A) Conversion assay u
Ad-wt-pIX-TK (1 AL, 1.6  109 v.p.; 5 AL, 8  109 v.p.; 20 AL, 3.2  1010 v.p.).
amounts of labeled 3H-thymidine substrate added for reaction. The light grey ba
phosphorylated 3H-thymidine product. Percent conversions are shown above. (B)
amounts of Ad-wt-pIX-TK: (?) 1 AL- 1.6  109 v.p., ( ) 5 AL- 8  109 v.p., an
deviation of three replicates.bolic kinetics. Together, these results demonstrate that the
kinase activity of the pIX-TK fusion protein incorporated
into adenoviral virions is functional.
MicroPET analysis of Ad-infected HEK293 cells
In order to determine the feasibility of using the pIX-TK
fusion protein incorporated within the Ad virions as a
reporter gene for microPET, Ad-wt-pIX-TK and a control
Ad-wt-E3-TK were used to infect HEK293 cells. To
preclude de novo protein pIX-TK synthesis, HEK293 cells
were infected for only 1 h prior to microPET scanning. In
the experiment shown in Fig. 9B, three 60-mm tissue culture
dishes were plated 12 h previously with 1  106 of the
HEK293 cell line. On the day of microPET scanning, to
each of the dishes was added 50 mCi of [18F]-FHBG.
Immediately thereafter, to one dish was added 1  109 v.p.
of Ad-wt-pIX-TK, to a second dish was added 1  109 v.p.
of Ad-wt-dE3, and to a third dish was added virus buffer
alone. The dishes were incubated for 1 h at 37 -C, followed
by three washes with 5 ml of PBS. The three dishes were
then stacked and placed in the microPET scanner (Fig. 9A),
and image data were acquired for 15 min. In the dish
corresponding to cells infected with Ad-wt-pIX-TK, specific
labeling and incorporation were observed in the region of
the tissue culture dish with cell adherence (Fig. 9B). In
contrast, in the dish corresponding to cells infected with Ad-
wt-E3-TK, only non-specific labeling was observed in the
edges of the tissue culture dish; this pattern was also
observed in the dish corresponding to uninfected cells.
These results confirm the utility of the pIX-TK fusion
protein for and form the foundation for further investigationpurified Ad virions, TK activity was determined in vitro by the amount of
sing purified Ad-wt-E3-TK (as a negative control) or increasing amounts of
The dark grey bars indicate the mean T standard deviation of three replicate
rs indicate mean T standard deviation of three replicate recoveries of the
Time course of phosphorylation of 3H-thymidine in vitro using increasing
d ( ) 20 AL- 3.2  1010 v.p. The values are expressed as mean T standard
Fig. 9. MicroPET scan of tissue culture dishes plated with HEK293 cells. (A) Three dishes were stacked and placed in the microPET scanner. (B) Cells in dish 1
were simultaneously infected with Ad-wt-pIX-TK and labeled [18F]-FHBG; cells in dish 2 were simultaneously infected with Ad-wt-dE3 and labeled [18F]-
FHBG; uninfected cells in dish 3 were labeled [18F]-FHBG. The dishes were incubated for 1 h followed by 15 min of data acquisition. Shown are images of
equivalent regions of interest from transverse, coronal, and sagittal planes through the dishes. (C) Cells in dish 1 were infected for 48 h with Ad-wt-pIX-TK;
cells in dish 2 were infected for 24 h with Ad-wt-pIX-TK; cells in dish 3 were uninfected. The dishes were labeled with [18F]-FHBG for 1 h followed by 15 min
of data acquisition. Shown is an image of a transverse plane through the dishes and plot of the coronal plane number in the scan versus the mean T standard
deviation of [18F] activity in each coronal plane.
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wt-pIX-TK in vivo with PET. However, since the [18F]-
FHBG and the virus were added simultaneously, this
experiment does not differentiate between the possibilities
that [18F]-FHBG was phosphorylated extracellularly by the
Ad-wt-pIX-TK virus which subsequently diffused into the
cell or that [18F]-FHBG was phosphorylated intracellularly.
To confirm that [18F]-FHBG is phosphorylated intra-
cellularly, three 60-mm tissue culture dishes were plated
with 1  106 of the HEK293 cell line and infected with Ad-
wt-pIX-TK for 24 or 48 h prior to labeling. At 12 h after
plating, one dish was infected with 1  109 v.p. (1.1  107
i.f.u.) of Ad-wt-pIX-TK. Likewise at 36 h after plating, one
dish was infected with an equivalent amount of Ad-wt-pIX-
TK. A third dish remained uninfected. At 60 h after plating
(i.e., 48 h, 24 h, and 0 h post-infection with Ad-wt-pIX-TK),
50 mCi of [18F]-FHBG was added to each of the dishes. The
dishes were incubated for 1 h at 37 -C, followed by three
washes with 5 ml of PBS. The three dishes were then
stacked and placed in the microPET scanner (Fig. 9A), and
image data were acquired for 15 min. In the dish
corresponding to cells infected for 48 h with Ad-wt-pIX-
TK, specific labeling and incorporation were observed in the
region of the tissue culture dish with cell adherence (Fig.
9C). Similar labeling was observed in the dish correspond-
ing to cells infected for 24 h with Ad-wt-pIX-TK.Importantly, in the dish corresponding to uninfected cells,
no labeling was observed. These results confirm that [18F]-
FHBG is phosphorylated intracellularly in cells infected
with Ad-wt-pIX-TK.Discussion
We have shown herein that our novel pIX-TK labeling
strategy for adenoviruses only marginally affected DNA
packaging and thermostability while maintaining DNA
replication, viral cytopathic effect/lateralization, and CAR-
dependent binding. Most importantly, the pIX-TK label
associated with the capsid demonstrated direct TK activity
in vitro in progeny virions as hypothesized. In addition,
infection of cells with an adenovirus containing the pIX-TK
fusion protein resulted in TK activity in cells with similar
activities on growth inhibition in the presence of GCV as
wild-type TK. In total, these data clearly establish the
functionality of the HSV-1 TK when incorporated into the
adenovirus capsid at the pIX locale.
The strategy we pursued involved the fusion of HSV-1
TK with the capsid protein pIX. The reasons for selecting
this locale include: (1) its function as a minor capsid protein
that is not absolutely required for replication, (2) its
externally exposed carboxy-terminus to which proteins
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and (3) its distant location in the hexon group of nine, which
would not affect the penton base as well as the fiber-knob
(Parks, 2005). The carboxy-terminus of pIX has now been
defined as a locus capable of presenting incorporated
ligands on the virus capsid surface (Campos et al., 2004;
Pereboeva et al., 2004; Vellinga et al., 2004). More recently,
the pIX-incorporated EGFP has been shown to be fully
functional, allowing visualization of labeled viral particles
for analytical purposes (Le et al., 2004; Meulenbroek et al.,
2004). The results of our current work on the pIX-TK
construct mark the largest fusion protein yet achieved in the
context of adenoviral capsid proteins, with the 375 amino
acid TK protein sequence and an 18 amino acid linker
sequence added to the carboxy-terminus of the 140 amino
acid pIX protein sequence. Thus, we have expanded the
upper limit to pIX fusion proteins, a size that has not yet to
be defined, and may be limited only by the size of the
adenoviral genome that can be incorporated into the virion
capsid.
We have shown herein that the pIX-TK labeling strategy
can be used to detect specific viral uptake in cells using
[18F]-FHBG by noninvasive imaging with microPET. One
of the most sensitive paradigms for gene transfer in vivo
imaging is the HSV-1 TK system (Blasberg, 2002). TK
catalyzes phosphorylation of the substrate, which becomes
trapped intracellularly. With an 18F positron emitting
substitution, it is possible to determine TK substrate
incorporation into cells by PET. PET is the current paradigm
for sensitivity to molecular events with in vivo imaging, and
animal microPET systems are now available providing
greater than 1-mm resolution (Weber and Bauer, 2004).
MicroPET is ideally suited to imaging molecular events in
animal studies because of its sensitivity and because the
animals can be repeatedly scanned to follow the course of
the disease (Luker et al., 2003). The utility of the HSV-1 TK
reporter gene technology has been demonstrated in vivo
using cancer xenografts models, in which microPET and
[18F]-FHBG have been used to visualize and monitor tumor
progression (Yaghoubi et al., 2005). In addition, microPET
offers the advantage of 3D tomographic image reconstruc-
tion over that of fluorescence or bioluminescence imaging
technologies.
Preclinically, microPET has been particularly useful in
monitoring extracellular receptor expression and in mon-
itoring the efficacy of gene delivery in mouse models (Chen
et al., 2004a). This method of in vivo detection has been
successfully used in mouse models. Injection of mice with
an Ad vector expressing HSV-1 TK (or an empty control
vector with no transgene) followed by PET imaging has
shown specific accumulation of 18F-labeled gancyclovir in
the liver (the major site of infection of the recombinant
adenovirus) (Chen et al., 2004b). In contrast, injection of
mice with a control vector has shown no accumulation of
label in the liver. PET technology offers the unique
opportunity to monitor delivery and uptake of the label invivo and to be able to predict and modify the treatment. In
oncology studies, PET provides a direct, whole body
assessment of the tumor size and the pattern of distribution
in normal and tumor tissues (Hustinx et al., 2002). This is
particularly important in developing human clinical trials,
where the use of PET imaging using [18F]-fluorodeoxyglu-
cose ([18F]-FDG) is already a clinically established techni-
que for the staging and follow-up of a wide variety of
neoplasms (Alavi et al., 2004). Recently, HSV-1 TK has
been proposed as a molecular probe for assessing transgene
expression in vivo and particularly for use in patients
(Jacobs et al., 2001).
While noninvasive imaging of adenoviral vector biodis-
tribution poses formidable challenges, our genetic adenovi-
rus pIX-TK labeling system may have an important impact
in the field of adenoviral virotherapy. Virotherapy exploits
the lytic property of virus replication to kill tumor cells
(Ries and Brandts, 2004). Because this approach relies on
viral replication, the virus can self-amplify and spread in the
tumor from an initial infection of only a few cells (Kirn,
2000). Although early attempts were abandoned because of
toxicity and inefficacy (Sinkovics and Horvath, 1993), the
virotherapy approach has reemerged with great promise, in
large part, due to better understanding of virus biology and
the ability to genetically modify viruses (Everts and Van der
Poel, 2005). In particular, conditionally replicative adeno-
viruses (CRAds) have been modified to be selective for
tumor cells (Oosterhoff and van Beusechem, 2004). The
potential of CRAds to be the next cancer therapy break-
through has been substantiated by their rapid translation into
human clinical trials (Nettelbeck, 2003). All of the initial
CRAd clinical trials have validated the safety of using
oncolytic adenoviruses for cancer therapy. Yet what these
trials failed to ascertain and what remain to be rigorously
determined are the crucial functions of CRAds: (1) selective
replication and killing, (2) robustness of replication, and (3)
spread of the virus.
Limited understanding of CRAd behavior is attributed to
lack of a noninvasive imaging system for monitoring
replicative agents. Several studies have attempted to address
this problem, using reporter genes such as green fluorescent
protein (GFP) (Yang et al., 2000), SSTR-2 (somatostatin
receptor type 2) (Zinn et al., 2000), sodium iodide
symporter (Cho et al., 2002), luciferase (Bhaumik and
Gambhir, 2002), and HSV-1 TK (Liang et al., 2002)
incorporated into oncolytic viruses. Detection was restricted
to infected cells expressing the reporter gene, which does
not truly represent the physical biodistribution of the virus
itself. Conventional imaging systems for gene therapy have
been designed for the detection of transgene expression of
such reporters, which correlated with therapeutic outcome
but could not show viral localization (Min and Gambhir,
2004).
Despite their utility for assessing gene delivery and
expression, these reporters by themselves are not suitable
for monitoring CRAd activity. The essence of oncolytic
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is at odds with reporter gene expression. In addition,
reporter gene expression may not truly represent the
underlying level of viral replication and the physical
distribution of viral progeny. No completed clinical trials
so far have incorporated a monitoring component into
replicative agents themselves, and therefore have had to rely
on conventional histology of biopsy specimens and analysis
of body fluids for the detection of virus. Such static
assessments fall short of accurately depicting the dynamic
mechanism of replicative agents. The ideal system for
monitoring CRAds and other oncolytic viruses should
provide the flexibility for dynamic detection of both viral
replication and spread to yield valuable and meaningful
data.
Our results confirm the utility of the pIX-TK fusion
protein for and form the foundation for further investigation
of [18F]-FHBG for noninvasive and repeated imaging of
Ad-wt-pIX-TK in vivo with PET technology. To this end,
our pIX-TK genetic adenovirus capsid labeling system may
offer unprecedented noninvasive dynamic imaging of CRAd
replication and spread. Not only may this tool be indis-
pensable in the preclinical development of advanced
generation CRAds, but it may also be practical in the
clinical setting to monitor the application of these agents for
cancer therapy.
We have shown herein that our novel genetic labeling
strategy of a pIX-TK fusion protein resulted in TK activity
in cells with similar activities on growth inhibition in the
presence of GCV as wild-type TK. One of the most
promising cancer gene therapy systems involves the use of
suicide gene therapy. At present, many experimental suicide
gene therapy approaches using the HSV-1 TK suicide gene
therapy model are in clinical trials (Fillat et al., 2003). The
HSV-1 TK enzyme is the target of drugs such as acyclovir
(ACV) and gancyclovir (GCV). Only cells expressing the
HSV-1 TK enzyme produce the monophosphate form of
these drugs. The monophosphate is subsequently converted
to the highly toxic triphosphate form, which causes
inhibition of cellular DNA polymerase and additional
genotoxic effects through incorporation into DNA. In the
absence of the drug, constitutive expression of the HSV-1
TK gene is not harmful: TK-transduced cells grow normally
both in vitro and in vivo. In fact, transgenic mice expressing
the HSV-1 TK gene have been produced with no toxicity in
the absence of GCV (Tian et al., 2003).
In vitro, cells expressing the Ad-wt-pIX-TK construct
were maximally inhibited by GCV in the 0.5 mM range, a
level that is readily achieved in patients treated with the
drug. These results suggest that suicide gene therapy may
represent an attractive adjuvant therapeutic approach using
adenoviral vectors modified with a pIX-TK fusion protein
and may enhance cell killing using the adenoviral virother-
apy approach. A potential advantage of combining the
suicide gene therapy approach is that even when less than
100% of the tumor is genetically modified, the entire tumormass can be eradicated through the ‘‘bystander effect’’ of
TK/GCV gene therapy (van Dillen et al., 2002). Thus, the
combination of suicide gene therapy and virotherapy may
provide an additional benefit for the pIX-TK fusion protein,
together with in vivo imaging by microPET.Materials and methods
Cell culture
Human embryonic kidney epithelial (HEK293) cells,
Chinese hamster ovary (CHO), and human lung adenocar-
cinoma A549 cells were obtained from and cultured in the
medium recommended by the American Type Culture
Collection (Manassas, VA). The adenovirus helper cell line
911 (Fallaux et al., 1996) was grown in DMEM supple-
mented with 10% FBS, 100 IU/mL penicillin, 100 Ag/mL
streptomycin, and 2 mM l-glutamine. All cell lines were
incubated at 37 -C and 5% CO2 under humidified
conditions.
Recombinant adenovirus construction
All viruses were constructed by homologous recombina-
tion in Escherichia coli using methods previously described
(He et al., 1998), using The HSV-1 TK gene from
PDC.SSTR.HSV-tk (Zinn et al., 2002) was cut with SalI
digestion (and blunt-ended by Klenow filling) followed by
BglII digestion. The excised HSV-1 TK fragment was
inserted into an E3-deleted shuttle plasmid pShuttleE3 after
digestion with KpnI (and blunt-ended by Klenow filling)
and with BamHI to generate pShuttle-E3-HSV1-tk. Homol-
ogous recombination was performed with plasmid PTG3602
(containing the wild-type E1, E3 Ad5 backbone) and the
resultant recombinant plasmid was linearized with PacI and
transfected into 911 cells to generate the Ad-wt-E3-TK
control virus. To construct the Ad-wt-pIX-TK virus, the
HSV-1 TK gene was inserted in-frame at the carboxyl
terminus of the adenovirus protein IX gene (NheI site)
within pShuttle.wt.E1-IX-flag (Le et al., 2004) after an 18
amino acid linker, SADDYKDDDDKLAGSGSG, contain-
ing the octapeptide DYKDDDDK FLAG-tag sequence.
Homologous recombination was performed with the result-
ing pShuttle.wt.E1-pIX-flag-TK and with plasmid
PTG3602AmpF2dE3 (containing the E1, E3 deleted Ad5
backbone) and the resultant recombinant plasmid was
linearized with PacI and transfected into 911 cells to
generate the Ad-wt-pIX-TK virus.
Virus propagation and purification
Viruses were propagated in 911 cells and HEK293 cells,
which do not express wild-type pIX. Viruses were purified by
double CsCl ultracentrifugation and dialyzed against phos-
phate-buffered saline with Mg2+, Ca2+, and 10% glycerol.
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(using absorbance at 260 nm) and infectious units (using a
plaque forming assay). Viruses were stored at 80 -C until
use. Final titers for the viruses were: Ad-wt-E3-TK = 58.0
v.p./i.f.u. (1.26 1011 v.p./mL; 2.17 109 i.f.u./mL), Ad-wt-
pIX-TK = 86.0 v.p./i.f.u. (1.60  1011 v.p./mL; 1.86  109
i.f.u./mL), Ad-wt-dE3 = 521 v.p./i.f.u. (2.10  1012 v.p./mL;
4.03  109 i.f.u./mL), and Ad-wt-E3-CD = 274 v.p./i.f.u.
(1.60  1011 v.p./mL; 5.85  108 i.f.u./mL).
Characterization of virus gradient fractions (Western blot
and DNA content assay)
After double CsCl ultracentrifugation which was retained
through yielding one tube from ten 150-mm tissue culture
dishes, the top and bottom bands were collected from the
bottom of tube by two drops each sample (¨100 Al).
Fractionated samples (10 Al) were ethanol precipitated,
pelleted, and resuspended with 20 Al RIPA buffer. Samples
(10 Al) were resolved with 10% SDS–PAGE and transferred
to a PVDF membrane (BioRad, Hercules, CA). Blotting was
performed with a primary monoclonal FLAG antibody
(1:2000 dilution, SIGMA, F3165) followed by a secondary
HRP-linked anti-mouse antibody (1:5000 dilution, Amer-
sham Pharmacia, Piscataway, NJ). Bands were detected
using a chemiluminescent ECL kit (Amersham Pharmacia).
DNA content was determined by measuring the absorbance
at 260 nm (MBA 2000, Perkin-Elmer, Shelton, CT).
Cytopathic effect assay
Five thousand 911 cells were infected with Ad-wt-dE3,
Ad-wt-E3-TK, and Ad-wt-pIX-TK (1.0, 0.1, and 0.01 i.f.u./
cell) in 100 Al of 5% DMEM medium without phenol red in
96-well plates (six replicates each plus six non-infected cells
as control). Cytopathic effect was measured by MTS assay
(Promega, Madison, WI) at 0, 2, 4, 6, 8, and 10 days post-
infection. Results were calculated as percent of non-infected
cells with blank values (medium only) subtracted.
Thermostability assay
Twenty thousand 911 cells were subcultured overnight
into 48-well plates with 150 Al DMEM medium containing
5% FBS. Prior to infection, the viruses were incubated for 0-,
5-, 10-, 20-, and 40-min time periods at 45 -C, and
subsequently, the heat-treated viruses were used to infect
the 911 cells (at a multiplicity of infection of 0.1 i.f.u. units/
cell). At 24 h post-infection, the cells were collected for total
DNA preparation, and viral replication was determined using
TaqMan real-time PCR of adenovirus E4 DNA. Genomic
DNA from the cells was isolated and cleaned using a Qiagen
Tissue Kit (Qiagen), following the instructions of the
manufacturer. The concentration of isolated DNA was
determined by spectrophotometry. TaqMan primers and
probe design, the forward primer, the reverse primer, andthe 6-carboxyfluorescein-labeled probe to amplify the E4
gene were designed by the Primer Express 1.0 software
(Perkin-Elmer, Foster City, CA) following the recommenda-
tions of the manufacturer. The sequences of the forward and
the reverse E4 primers were 5V-GGAGTGCGCCGAGA-
CAAC-3V(annealing between residues 816 and 833 of the E4
orf6 open reading frame) and 5V-ACTACGTCCGGCGTTC-
CAT-3V (annealing between residues 883 and 865), respec-
tively. The sequence of the TaqMan probe was 5V-
TGGCATGACACTACGACCAACACGATCT-3V (anneals
between residues 836 and 863). The HSV-1 TK primer pairs
(forward, 5V-GCACGTCTTTATCCTGGATTACG-3V and
reverse, 5V-TGGATCATCCCGGAGGTAAG-3V) and probe
(5V-CCGGGACGCCCTGCTGCA-3V) were selected to be
unique and non-homologous to any known human sequence.
The probes were labeled with a reporter fluorescent dye FAM
(6-carboxyfluorescein) at the 5V end and a quencher-
fluorescent dye TAMRA (6-carboxy-tetramethylrhodamine)
at the 3Vend.
With optimized concentration of primers and probe, the
components of real-time PCR mixtures were designed to
result in a master mix with a final volume of 10 Al/reaction
containing 1  Universal PCR Master Mix (Applied
Biosystems, Foster City, CA), 100 nM forward primer,
100 nM reverse primer, 1 nM probe, and 0.025% BSA. For
the assay, 1 Al of extracted DNA sample was added to 10 Al
of PCR mixture in each reaction capillary. A no-template
control received 10 Al of reaction mixture with 1 Al of water.
All capillaries were then sealed and centrifuged using an LC
Carousel Centrifuge (Roche Molecular Biochemicals, Indi-
anapolis, IN) to facilitate mixing. All PCR reactions were
carried out using a LightCycler System (Roche Molecular
Biochemicals). The thermal cycling conditions were 10 min
at 95 -C and 40 cycles of 15 s at 95 -C and 1 min at 60 -C.
Car binding assay
The CHO and A549 cell lines (2  105 cells in 100 Al of
medium) were incubated at 4 -C with shaking using 100 Al
of buffer alone or using 100 Al of buffer containing 2.5 Ag/
mL recombinant Ad5 fiber knob. After 1 h, viruses were
added directly (at a multiplicity of infection of 5000 i.f.u./
cell, based on TaqMan real-time PCR E4 DNA copy
numbers). Following shaking for another hour at 4 -C, the
cells were washed three times with 1% BSA/PBS buffer,
collected for total DNA preparation, and then quantitated
using TaqMan real-time PCR with E4 primers as described
above.
Cell killing assay
Five thousand 911 cells were plated overnight into each
well of 96-well tissue culture plates in 100 Al of DMEM
medium without phenol red containing 5% FBS. The cells
were infected with Ad-wt-dE3, Ad-wt-E3-TK, and Ad-wt-
pIX-TK (at 1.0, 0.1, and 0.01 infectious units/cell) using
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as a control. At 12 h post-infection, GCV was added to the
cells at increasing concentrations (0.125, 0.5, and 1.0 mM).
Cell killing was measured by MTS assay (Promega,
Madison, WI) at 4 days post-infection. Results were
calculated as percent of non-infected cells with blank values
(medium only) subtracted.
pIX-TK conversion assay
Conversion of [3H]-thymidine in vitro was analyzed by a
modified version of a previously reported protocol (Gerber
and Folkers, 1996). Triple sets of reaction mixtures
containing 50 mM Tris (pH 7.2), 5 mM ATP, 5 mM MgCl2,
2 mg/mL BSA, and 1 mM of [3H]-thymidine (Sigma-
Aldrich, St. Louis, MO), in a final volume of 330 Al, were
incubated at 37 -C with increasing amount of purified Ad-
wt-pIX-TK (0, 1.6  109, 8  109, and 3.2  1010 v.p.).
Three corresponding blank reactions were performed using
1 mM unlabeled thymidine. Equivalent reactions were
performed using purified Ad-wt-E3-TK (1.26  1010 v.p.)
as negative controls. After 40 min, the reaction mixtures
were inactivated by heating to 95 -C for 3 min followed by
centrifugation for 1 min at 14,000  g. For determination of
the total amount of [3H]-labeled thymidine converted to its
phosphorylated form, a DEAE-cellulose binding assay was
performed. Three triplicates of 10 Al from each reaction
mixture were transferred onto 200 Al DEAE-cellulose
(buffered with 100 mM Tris, pH 7.2) and mixed by
vortexing in order to bind the negatively charged phos-
phorylated thymidine. After binding, the mixtures were
centrifuged and washed two times with 4 mM ammonium
acetate and once with methanol to remove the non-
phosphorylated thymidine. The cellulose pellets were trans-
ferred directly into scintillation vials containing 8 ml of
scintillation cocktail and the amount of converted [3H]-
thymidine was determined using a scintillation counter.
Results were calculated as percent total conversion using the
amount of total labeled substrate obtained from sets of 10 Al
triplicates from each reaction mixture pipetted directly into
scintillation vials containing 8 ml of scintillation cocktail
and counted.
MicroPET scan of Ad-infected HEK293 cells
PET studies were performed using a microPET rodent
four-ring system (model R4) from CTI Concorde Micro-
systems, LLC (Knoxville, TN). In brief, the system operates
in three dimensions and is composed of 6144 lutetium
oxyorthosilicate crystal (LSO) detector elements, with a 7.8
cm axial and a 10 cm transaxial field-of-view. The 9-[4-
[18F]-fluoro-3-(hydroxymethyl)butyl]guanine analog ([18F]-
FHBG) has been used as a reporter probe to image the
expression of the herpes simplex virus type 1 (HSV-1)
thymidine kinase (TK) reporter gene in living organisms and
has been suggested to be a more effective probe for in vivoimaging than other acycloguanosine analogs (Alauddin et
al., 2004). The HSV-1 TK phosphorylates [18F]-FHBG to its
monophosphate form, leading to intracellular accumulation
(Green et al., 2002). Cellular retention of radioactivity is,
therefore, an indicator of HSV-1 TK gene expression.
Synthesis and purification of [18F]-FHBG have been
described previously (Parks, 2005).
For in vitro experiments, three 60-mm tissue culture
dishes (Costar, Corning, NY) were plated for 12 h
previously with 1  106 of the HEK293 cell line in 3 ml
of complete medium. On the day of microPET scanning, to
each of the dishes was added 50 mCi of [18F]-FHBG.
Immediately thereafter, to one plate was added 1  109 v.p.
(1.1  107 i.f.u.) of Ad-wt-pIX-TK, to a second dish was
added 1  109 v.p. (1.9  106 i.f.u.) of the control Ad-wt-
dE3 virus, and to a third dish was added PBS alone. The
plates were incubated for 1 h at 37 -C, followed by three
washes with 5 ml of PBS. The three dishes were stacked and
placed in the microPET scanner, and image data were
acquired for 15 min. MicroPET images were reconstructed
by using an iterative reconstruction technique.
To confirm these results, three 60-mm tissue culture
dishes (Costar, Corning, NY) were plated for 12 h
previously with 1  106 of the HEK293 cell line in 3 ml
of complete medium. At 12 h after plating, one dish was
infected with 1  109 v.p. (1.1  107 i.f.u.) of Ad-wt-pIX-
TK. Likewise, at 36 h after plating, one dish was infected
with an equivalent amount of Ad-wt-pIX-TK. A third dish
remained uninfected. At 60 h after plating (48 h, 24 h, and 0
h post-infection with Ad-wt-pIX-TK), 50 mCi of [18F]-
FHBG was added to each of the dishes. The plates were
incubated for 1 h at 37 -C, followed by three washes with 5
mL of PBS. The three dishes were stacked and placed in the
microPET scanner, and image data were acquired for 15
min. MicroPET images were reconstructed by using an
iterative reconstruction technique.Acknowledgments
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